Start Reading

August 22 2017 Issue: Oral fluoroquinolones and risk of secondary pseudotumor cerebri syndrome

Ratings:
0 page

Summary

Show description/summary:1) Oral fluoroquinolones and risk of secondary pseudotumor cerebri syndrome2) Neurology Today: FDA Approves Edaravone for ALS: Phase 3 Trial Finds It Slows ProgressionThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the August 22, 2017 issue of Neurology. In the first segment, Dr. Halley Alexander talks with Mr. Mohit Sodhi about his paper on oral fluoroquinolones and risk of secondary pseudotumor cerebri syndrome. In the second part of the podcast, Dr. Kelly Gwathmey focuses her interview with Dr. Terry Heiman-Patterson on a Neurology Today® story about the FDA-approval of edaravone for the treatment of ALS. Disclosures can be found at Neurology.org.DISCLOSURES: All participants report no disclosures.

Read on the Scribd mobile app

Download the free Scribd mobile app to read anytime, anywhere.